Apr. 2 at 12:36 AM
Even though
$SLNO is up ~20% the last 2 days, SLNO still trades @ meaningfully lower multiples of analyst consensus revenue estimates than peer commercial-stage non-oncology focused bios.
The attachment provides the raw data used to calculate these multiples. Note none of the 4 peers generated gross margins over 90% in FY25 where SLNO's gross margins were 99%. Gross margin is not considered when comparing revenue multiples.
For perspective, analysts project SLNO to generate more revenues over the next 10 years as
$MIRM yet SLNO trades at 1/3 MIRM's market cap. SLNO's cash is roughly 25% of its market cap.
This suggests SLNO offers a compelling risk v reward profile if (2 HUGE IFs) analyst consensus revenue estimates are credible AND if Vykat's value proposition merits peer multiples.
Again this is in no way to criticize nor bash MIRM, but rather to highlight SLNO.
$TARS &
$KNSA also trade at lower multiples (even after KNSA's run).
$TGTX multiples are after a 20% gains the last 3 weeks
